Clinical Trials Browser

Phase 2 × Interventional × Adenocarcinoma, Clear Cell × Clear all

Uterine Cervical Neoplasms, Ovarian Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms, Adenocarcinoma, Clear Cell

NCT03355976 2026-04-02

BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas

Phase 2 Active not recruiting

46 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Recurrence, Adenocarcinoma, Clear Cell

NCT05500391 2026-03-18

SUR-CAN

Phase 2 Recruiting

88 enrolled

CNSEndocrineGastrointestinalNETSarcoma

Carcinosarcoma, Glioma, Seminoma, Adenocarcinoma, Clear Cell, Carcinoma, Small Cell, Sex Cord-Gonadal Stromal Tumors, Neuroendocrine Tumors, Gastrointestinal Stromal Tumors

NCT05460000 2026-02-12

N-Plus

Phase 2 Recruiting

640 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Adenocarcinoma, Clear Cell

NCT05032040 2025-02-07

A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies

Phase 2 Active not recruiting

170 enrolled

GenitourinaryGynecologic

Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms, Adenocarcinoma, Clear Cell

NCT03241745 2024-12-27

A Study of Nivolumab in Selected Uterine Cancer Patients

Phase 2 Completed

35 enrolled 8 charts

GynecologicSarcoma

Carcinosarcoma, Leiomyosarcoma, Uterine Neoplasms, Endometrial Neoplasms, Adenocarcinoma, Clear Cell

NCT00563784 2019-11-20

TARCEVA (Erlotinib) in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)

Phase 2 Completed

68 enrolled 11 charts

Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms, Adenocarcinoma, Clear Cell, Carcinoma, Giant Cell

NCT01824615 2018-07-18

Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma

Phase 2 Completed

30 enrolled

Gynecologic

Ovarian Neoplasms, Adenocarcinoma, Clear Cell

NCT00455975 2014-12-22

High-dose Bevacizumab in Advanced Renal Carcinoma Patients

Phase 2 Completed

119 enrolled 8 charts

Genitourinary

Kidney Neoplasms, Adenocarcinoma, Clear Cell

NCT00231829 2012-04-24

A Pilot Study of Celecoxib in Patients With Grade 2 or 3 Uterine Cancers

Phase 2 Terminated

23 enrolled

Gynecologic

Uterine Neoplasms, Adenocarcinoma, Clear Cell

NCT00226798 2006-01-04

Immunochemotherapy for Metastatic Renal Cell Carcinoma

Phase 2 Unknown

45 enrolled

Adenocarcinoma, Clear Cell

Clinical Trials

DOVE

BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas

SUR-CAN

N-Plus

A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies

A Study of Nivolumab in Selected Uterine Cancer Patients

TARCEVA (Erlotinib) in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)

Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma

High-dose Bevacizumab in Advanced Renal Carcinoma Patients

A Pilot Study of Celecoxib in Patients With Grade 2 or 3 Uterine Cancers

Immunochemotherapy for Metastatic Renal Cell Carcinoma